Breaking News: MRK – Market Insights, Analysis & Latest Updates

BIIB
MRK

BMO cuts rating on Merck and Biogen, on lack of near term catalyst

BMO Capital Markets downgraded Merck and Biogen due to revenue concerns and lack of growth catalysts, lowering stock targets and indicating limited near-term opportunities for recovery.

investing.com • 20/12/2024 - 14:34 PM

MRK

Merck's HIV treatment meets main goal of two late-stage studies

Merck's experimental drug for HIV-1 treatment achieved success in two late-stage clinical studies.

investing.com • 19/12/2024 - 11:58 AM

MRK
VKTX

Viking shares tumble after Merck inks deal with Hansoh Pharma

Viking shares declined by 5.5% following a licensing agreement between Hansoh Pharma and Merck regarding the development of a new metabolic disorder treatment.

investing.com • 18/12/2024 - 13:12 PM

3692
MRK

Merck stock rises following Hansoh Pharma deal

Merck & Co. licenses obesity drug HS-10535 from Hansoh Pharmaceutical, paying $112M upfront and up to $1.9B in milestones, aiming to expand its obesity treatment portfolio.

investing.com • 18/12/2024 - 12:24 PM

Unsupported price hikes added $815 million to US drug spending in 2023

A report reveals five drugs accounted for $815 million in U.S. spending increases in 2023 without clinical evidence, highlighting ongoing pricing issues in the pharmaceutical industry.

investing.com • 12/12/2024 - 13:03 PM

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.35%

U.S. stocks fell Tuesday, driven by losses in major sectors. Dow, S&P 500, and NASDAQ indexes declined, with notable shifts in individual stock performances.

investing.com • 10/12/2024 - 21:30 PM

BofA reinstates pharma coverage

Bank of America reviews 11 U.S. pharma stocks, highlighting growth potential and challenges amid patent cliffs and pricing pressures while recommending buy, neutral, and underperform ratings.

investing.com • 10/12/2024 - 14:30 PM

MRK

HSBC upgrades Merck stock to Buy on 2025 opportunities

HSBC upgrades Merck & Company to Buy, maintaining a $130 price target, citing confidence in their oncology strategy despite potential risks in Gardasil and Keytruda growth.

investing.com • 04/12/2024 - 14:15 PM

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.17%

U.S. stocks were mixed with notable gains in tech and telecom sectors, while declines were seen in consumer goods and financials. Key stocks reached all-time highs.

investing.com • 03/12/2024 - 21:30 PM

MRK

Merck advances with FDA breakthrough tag for cancer drug

Merck & Co's FDA Breakthrough Therapy designation for sacituzumab tirumotecan aids advanced NSCLC treatment. Also approved in China for triple-negative breast cancer, accelerating its global development.

investing.com • 03/12/2024 - 11:57 AM

Currency